

Elisabetta Romagnoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5410270/publications.pdf>

Version: 2024-02-01

101
papers

3,353
citations

126858

33
h-index

161767

54
g-index

101
all docs

101
docs citations

101
times ranked

3723
citing authors

#	ARTICLE	IF	CITATIONS
1	Short and Long-Term Variations in Serum Calcitropic Hormones after a Single Very Large Dose of Ergocalciferol (Vitamin D2) or Cholecalciferol (Vitamin D3) in the Elderly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3015-3020.	1.8	286
2	Skeletal involvement in patients with diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2004, 20, 196-204.	1.7	135
3	Trabecular Bone Score (TBS): An indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. <i>Bone</i> , 2013, 53, 154-159.	1.4	135
4	Hypovitaminosis D in an Italian population of healthy subjects and hospitalized patients. <i>British Journal of Nutrition</i> , 1999, 81, 133-137.	1.2	124
5	Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. <i>Journal of Internal Medicine</i> , 1990, 227, 11-14.	2.7	111
6	The risk of fractures in postmenopausal women with primary hyperparathyroidism. <i>European Journal of Endocrinology</i> , 2006, 155, 415-420.	1.9	87
7	Effect of a Single Oral Dose of 600,000 IU of Cholecalciferol on Serum Calcitropic Hormones in Young Subjects with Vitamin D Deficiency: A Prospective Intervention Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4771-4777.	1.8	84
8	Long-Term Bioavailability After a Single Oral or Intramuscular Administration of 600,000 IU of Ergocalciferol or Cholecalciferol: Implications for Treatment and Prophylaxis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2709-2715.	1.8	80
9	Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1991, 51, 517-524.	0.6	78
10	Quality of life in ambulatory postmenopausal women: the impact of reduced bone mineral density and subclinical vertebral fractures. <i>Osteoporosis International</i> , 2004, 15, 975-980.	1.3	77
11	Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. <i>Osteoporosis International</i> , 2005, 16, 805-812.	1.3	74
12	Parathyroid carcinoma. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2018, 32, 877-889.	2.2	70
13	Effect of estrogen deficiency on IGF-I plasma levels: Relationship with bone mineral density in perimenopausal women. <i>Calcified Tissue International</i> , 1993, 53, 1-6.	1.5	69
14	Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2006, 134, 485-490.	1.2	69
15	Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study. <i>Acta Diabetologica</i> , 2015, 52, 727-732.	1.2	69
16	Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 321-326.	1.8	67
17	CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort. <i>Cellular Oncology (Dordrecht)</i> , 2012, 35, 411-422.	2.1	67
18	MANAGEMENT OF ENDOCRINE DISEASE: Value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. <i>European Journal of Endocrinology</i> , 2013, 169, R59-R69.	1.9	65

#	ARTICLE	IF	CITATIONS
19	Several approaches for vitamin D determination by surface plasmon resonance and electrochemical affinity biosensors. <i>Biosensors and Bioelectronics</i> , 2013, 40, 350-355.	5.3	63
20	Trabecular bone mineral density in primary hyperparathyroidism: relationship to clinical presentation and biomarkers of skeletal turnover. <i>Bone and Mineral</i> , 1993, 20, 113-123.	2.0	54
21	Bone damage in type 2 diabetes mellitus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 1151-1157.	1.1	52
22	Serum ionized calcium, parathyroid hormone and related variables: effect of age and sex. <i>Bone and Mineral</i> , 1993, 23, 183-193.	2.0	50
23	Potential Clinical Utility of a New IRMA for Parathyroid Hormone in Postmenopausal Patients with Primary Hyperparathyroidism. <i>Clinical Chemistry</i> , 2004, 50, 626-631.	1.5	45
24	Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?. <i>Clinical Endocrinology</i> , 2004, 60, 81-86.	1.2	45
25	The Effects of Alendronate Treatment in Osteoporotic Patients Affected by Monoclonal Gammopathy of Undetermined Significance. <i>Calcified Tissue International</i> , 2008, 82, 418-426.	1.5	45
26	Assessment of trabecular bone score (TBS) in overweight/obese men: effect of metabolic and anthropometric factors. <i>Endocrine</i> , 2016, 54, 342-347.	1.1	45
27	Gender Differences in Serum Markers of Bone Resorption in Healthy Subjects and Patients with Disorders Affecting Bone. <i>Osteoporosis International</i> , 2002, 13, 171-175.	1.3	44
28	Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. <i>Osteoporosis International</i> , 2006, 17, 478-483.	1.3	41
29	Diagnostic accuracy of 3T magnetic resonance imaging in the preoperative localisation of parathyroid adenomas: comparison with ultrasound and 99mTc-sestamibi scans. <i>European Radiology</i> , 2018, 28, 4900-4908.	2.3	41
30	Diagnostic Performance of Vertebral Fracture Assessment by the Lunar iDXA Scanner Compared to Conventional Radiography. <i>Calcified Tissue International</i> , 2012, 91, 335-342.	1.5	40
31	Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery. <i>European Journal of Endocrinology</i> , 1994, 130, 587-591.	1.9	38
32	Bone metabolism in ochronotic patients. <i>Journal of Internal Medicine</i> , 2003, 254, 296-300.	2.7	37
33	Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1321-1326.	1.8	36
34	Serum osteocalcin and bone mineral density at various skeletal sites: A study performed with three different assays. <i>Translational Research</i> , 1997, 129, 422-429.	2.4	35
35	The combination of FRAX and Ageing Male Symptom scale better identifies treated HIV males at risk for major fracture. <i>Clinical Endocrinology</i> , 2012, 77, 672-678.	1.2	32
36	Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. <i>Clinical Endocrinology</i> , 2013, 79, 20-26.	1.2	32

#	ARTICLE	IF	CITATIONS
37	Assessment of fracture risk by the FRAX algorithm in men and women with and without type 2 diabetes mellitus: a cross-sectional study. <i>Diabetes/Metabolism Research and Reviews</i> , 2014, 30, 313-322.	1.7	32
38	Quantitative ultrasound assessment of bone in patients with primary hyperparathyroidism. <i>Calcified Tissue International</i> , 1995, 56, 526-528.	1.5	30
39	Biomarkers of Bone Turnover after a Short Period of Steroid Therapy in Elderly Men. <i>Clinical Chemistry</i> , 2001, 47, 1314-1316.	1.5	30
40	Regulation of PTH secretion by 25-hydroxyvitamin D and ionized calcium depends on vitamin D status: A study in a large cohort of healthy subjects. <i>Bone</i> , 2010, 47, 626-630.	1.4	30
41	Parathyroidectomy eliminates arrhythmic risk in primary hyperparathyroidism, as evaluated by exercise test. <i>European Journal of Endocrinology</i> , 2013, 169, 255-261.	1.9	29
42	Vertebral morphometry by dual-energy X-ray absorptiometry (DXA) for osteoporotic vertebral fractures assessment (VFA). <i>Radiologia Medica</i> , 2012, 117, 1374-1385.	4.7	27
43	Vitamin D status in primary hyperparathyroidism: effect of genetic background. <i>Endocrine</i> , 2017, 55, 266-272.	1.1	24
44	Assessment of Serum Total and Bone Alkaline Phosphatase Measurement in Clinical Practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 1998, 36, 163-8.	1.4	23
45	HypoparaNet: A Database of Chronic Hypoparathyroidism Based on Expert Medical-Surgical Centers in Italy. <i>Calcified Tissue International</i> , 2018, 103, 151-163.	1.5	23
46	Long-term effect of testosterone replacement therapy on bone in hypogonadal men with Klinefelter Syndrome. <i>Endocrine</i> , 2018, 61, 327-335.	1.1	23
47	Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I-A osteogenesis imperfecta. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 1261-1265.	1.5	21
48	Sex hormones and bone health in males. <i>Archives of Biochemistry and Biophysics</i> , 2010, 503, 110-117.	1.4	21
49	Metabolic Changes Following 500µg Monthly Administration of Calcidiol: A Study in Normal Females. <i>Calcified Tissue International</i> , 2011, 89, 252-257.	1.5	21
50	Arrhythmias in primary hyperparathyroidism evaluated by exercise test. <i>European Journal of Clinical Investigation</i> , 2013, 43, 208-214.	1.7	21
51	Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. <i>European Journal of Endocrinology</i> , 2014, 170, K1-K4.	1.9	20
52	Vitamin D supplementation: when and how?. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 603-607.	1.8	20
53	Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 866-8.	1.8	20
54	Circulating levels of insulin-like growth factor binding protein 3 (IGFBP-3) and insulin-like growth factor I (IGF-I) in perimenopausal women. <i>Osteoporosis International</i> , 1994, 4, 305-308.	1.3	19

#	ARTICLE	IF	CITATIONS
55	Secondary Osteoporosis in Men and Women: Clinical Challenge of an Unresolved Issue. <i>Journal of Rheumatology</i> , 2011, 38, 1671-1679.	1.0	19
56	Muscle strength and bone in healthy women: effect of age and gonadal status. <i>Hormones</i> , 2012, 11, 325-332.	0.9	19
57	Effects of ipriflavone on bone remodeling in primary hyperparathyroidism. <i>Bone and Mineral</i> , 1992, 19, S27-S33.	2.0	18
58	Temporal relationship between bone loss and increased bone turnover: A longitudinal study following natural menopause. <i>Journal of Endocrinological Investigation</i> , 1995, 18, 723-728.	1.8	17
59	Effect of gender and geographic location on the expression of primary hyperparathyroidism. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 123-6.	1.8	17
60	Clinical Validation of a New Immunoradiometric Assay for Intact Human Osteocalcin. <i>Calcified Tissue International</i> , 1999, 64, 365-369.	1.5	16
61	Impaired Immune Function in Patients With Chronic Postsurgical Hypoparathyroidism: Results of the EMPATHY Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e2215-e2227.	1.8	16
62	Clinical value of the measurement of bone remodelling markers in primary hyperparathyroidism. <i>Journal of Endocrinological Investigation</i> , 1989, 12, 537-542.	1.8	15
63	Vertebral morphometry by X-ray absorptiometry: Which reference data for vertebral heights?. <i>Bone</i> , 2011, 49, 526-536.	1.4	15
64	Acute and chronic effects of hypercalcaemia on cortical excitability as studied by 5 Hz repetitive transcranial magnetic stimulation. <i>Journal of Physiology</i> , 2011, 589, 1619-1626.	1.3	15
65	Two-site assay of intact parathyroid hormone in primary hyperparathyroidism: studies in basal conditions, following adenoma removal and during calcium and EDTA infusion. <i>Clinica Chimica Acta</i> , 1990, 190, 239-248.	0.5	14
66	The effects of oophorectomy on skeletal metabolism. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1990, 37, 457-459.	1.2	13
67	Age-related changes in the global skeletal uptake of technetium-99m methylene diphosphonate in healthy women. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1473-1477.	2.2	13
68	Intermittent High Doses of Vitamin D: A Need for Further Studies?. <i>Calcified Tissue International</i> , 2013, 92, 487-488.	1.5	12
69	Concurrent improvement of neuromuscular and skeletal involvement following surgery for primary hyperparathyroidism. <i>Journal of Neurology</i> , 1992, 239, 57-57.	1.8	11
70	The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 559-565.	1.8	11
71	The effect of parathyroidectomy on chronic constipation in patients affected by primary hyperparathyroidism. <i>Journal of Bone and Mineral Metabolism</i> , 2013, 31, 690-694.	1.3	10
72	Uneven Deficits in Vertebral Bone Density in Postmenopausal Patients with Primary Hyperparathyroidism as Evaluated by Posterior Anterior and Lateral Dual-Energy Absorptiometry. <i>Osteoporosis International</i> , 2002, 13, 618-623.	1.3	9

#	ARTICLE	IF	CITATIONS
73	The Effect of Recombinant PTH(1-34) and PTH(1-84) on Serum Ionized Calcium, 1,25-Dihydroxyvitamin D, and Urinary Calcium Excretion: A Pilot Study. <i>Calcified Tissue International</i> , 2009, 85, 287-292.	1.5	9
74	Letter to the editor: Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 335-336.	3.1	9
75	Quality of life in patients with primary hyperparathyroidism. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 113-121.	0.7	9
76	Conventional and new diagnostic applications of a two-site immunochemiluminometric assay for parathyroid hormone S. Minisola. <i>Journal of Endocrinological Investigation</i> , 1992, 15, 483-489.	1.8	8
77	Serum osteocalcin in metabolic bone diseases: What is its real significance?. <i>Journal of Endocrinological Investigation</i> , 1993, 16, 277-279.	1.8	8
78	Short-term effects of surgery in post-menopausal patients with primary hyperparathyroidism and normal bone turnover. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 575-579.	1.8	8
79	Hypovitaminosis D in primary hyperparathyroidism: to treat or not to treat? That is the question. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 413-414.	1.8	8
80	Pulmonary lymphangioliomyoma in a patient with multiple endocrine neoplasia Type I. <i>Journal of Endocrinological Investigation</i> , 1997, 20, 282-285.	1.8	7
81	Awareness, attitudes and opinions on osteoporosis of primary care physicians working in the metropolitan area of Rome: A brief report. <i>Aging Clinical and Experimental Research</i> , 2000, 12, 240-244.	1.4	7
82	Phalangeal Quantitative Ultrasound and Bone Mineral Density in Evaluating Cortical Bone Loss: A Study in Postmenopausal Women With Primary Hyperparathyroidism and Subclinical Iatrogenic Hyperthyroidism. <i>Journal of Clinical Densitometry</i> , 2009, 12, 456-460.	0.5	7
83	Effects of Strontium Ranelate Administration on Calcium Metabolism in Female Patients with Postmenopausal Osteoporosis and Primary Hyperparathyroidism. <i>Calcified Tissue International</i> , 2013, 92, 15-22.	1.5	7
84	Incidence and all-cause mortality for hip fracture in comparison to stroke, and myocardial infarction: a fifteen years population-based longitudinal study. <i>Endocrine</i> , 2017, 58, 320-331.	1.1	7
85	Parathyroid storm: Immediate recognition and pathophysiological considerations. <i>Bone</i> , 1993, 14, 703-706.	1.4	6
86	Impact of fractures on health care in a major university hospital in Rome. <i>Aging Clinical and Experimental Research</i> , 2003, 15, 505-511.	1.4	6
87	Estimate of body composition by Hume's equation: validation with DXA. <i>Endocrine</i> , 2015, 49, 65-69.	1.1	6
88	Massive Tumoral Calcinosis in a Patient on Long-Term Hemodialysis. <i>Journal of Bone and Mineral Research</i> , 2000, 15, 2056-2057.	3.1	4
89	Effect of a single oral dose of 600,000 IU of cholecalciferol on muscle strength: a study in young women. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 1051-4.	1.8	4
90	Osteoprotegerin Serum Levels in Primary Hyperparathyroidism and Changes Following Surgery. <i>Hormone and Metabolic Research</i> , 2014, 46, 375-375.	0.7	3

#	ARTICLE	IF	CITATIONS
91	Reversal of Decreased Bone Mass by Antibiotic Treatment in a Patient With Whipple's Disease. American Journal of the Medical Sciences, 1996, 311, 145-147.	0.4	3
92	Studies on the clinical significance of serum $\hat{1}\pm 2$ HS-glycoprotein measurement in metabolic bone diseases. Clinica Chimica Acta, 1990, 189, 245-248.	0.5	2
93	Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2007, 356, 2223-2224.	13.9	2
94	Measuring serum calcium before and after teriparatide treatment. Osteoporosis International, 2008, 19, 1807-1807.	1.3	2
95	Coexistent multiple myeloma and MEN type 1.. Postgraduate Medical Journal, 1990, 66, 879-880.	0.9	1
96	Acute Management of Hypercalcemia. , 2015, , 617-629.		1
97	Comment on Marked Improvement in Bone Mass after Parathyroidectomy in Osteitis Fibrosa Cysticag. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3758-3760.	1.8	1
98	Marked Improvement in Bone Mass After Parathyroidectomy in Osteitis Fibrosa Cystica--Authors' Response*h. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3760-3761.	1.8	1
99	Letter to the Editor: Comments on "Are biochemical markers of bone turnover representative of bone histomorphometry in 370 postmenopausal women?" by Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R.. Journal of Clinical Endocrinology and Metabolism, 2016, 101, L17-L18.	1.8	1
100	Therapy of Osteoporosis. Medical Radiology, 2013, , 5-13.	0.0	0
101	Skeletal Alterations and Parathyroid Function. , 2018, , 75-82.		0